Loading...
Docoh

Takeda Pharmaceutical (TAK)

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

TAK stock data

Analyst ratings and price targets

Last 3 months

Calendar

29 Jun 22
27 Sep 22
Quarter (USD) Mar 22 Mar 21 Mar 20 Mar 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Mar 22 Mar 21 Mar 20 Mar 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
1 Jul 22 Takeda Pharmaceutical Series A Convertible Preferred Stock Common Stock Other Acquire J Yes No 40.08 1,000,000 40.08M 1,000,000
1 Jul 22 Takeda Pharmaceutical Series A Convertible Preferred Stock Common Stock Other Dispose J Yes No 40.08 1,000,000 40.08M 0
1 Jul 22 Takeda Pharmaceutical Common Stock Other Acquire J Yes No 0 5,750,000 0 5,750,000
1 Jul 22 Takeda Pharmaceutical Common Stock Other Dispose J Yes No 0 5,750,000 0 0
1 Jul 22 Takeda Pharmaceutical Series A Convertible Preferred Stock Common Stock Other Acquire J Yes No 0 1,250 0 1,250
1 Jul 22 Takeda Pharmaceutical Series A Convertible Preferred Stock Common Stock Other Dispose J Yes No 0 1,250 0 0
14 Mar 22 Takeda Pharmaceutical Common Stock Sell Dispose S No No 19 18 342 7,459,286
14 Mar 22 Takeda Pharmaceutical Common Stock Acquire X No No 0 7,359,304 0 7,459,304
14 Mar 22 Takeda Pharmaceutical Warrants Common Stock Dispose X No No 0 7,359,304 0 0
13F holders Current Prev Q Change
Total holders 311 341 -8.8%
Opened positions 33 50 -34.0%
Closed positions 63 94 -33.0%
Increased positions 98 89 +10.1%
Reduced positions 96 116 -17.2%
13F shares Current Prev Q Change
Total value 20.68B 24.85B -16.8%
Total shares 142.67M 144.84M -1.5%
Total puts 4.66M 5.35M -12.9%
Total calls 4.51M 6.32M -28.6%
Total put/call ratio 1.0 0.8 +21.9%
Largest owners Shares Value Change
Glenview Capital Management 27.44M $472.03M +3.8%
Paulson & Co. 13.24M $227.81M 0.0%
Baupost 9.43M $162.28M -0.0%
Adelphi Capital 8.99M $154.65M +13.4%
Vanguard 6.15M $105.85M -8.1%
MCQEF Macquarie 5.3M $91.17M -3.7%
TROW T. Rowe Price 4.16M $71.49M -0.5%
BAC Bank Of America 4.05M $69.61M +8.1%
NTRS Northern Trust 3.92M $67.35M -3.6%
Mondrian Investment Partners 3.64M $61.87M +6.7%
Largest transactions Shares Bought/sold Change
FMR 604.99K -2.1M -77.7%
LMR Partners 2.54M -2.03M -44.4%
GS Goldman Sachs 2.06M +1.54M +294.3%
NINE MASTS CAPITAL 0 -1.47M EXIT
GMT Capital 3.15M +1.18M +59.6%
Adelphi Capital 8.99M +1.06M +13.4%
Glenview Capital Management 27.44M +1.01M +3.8%
Renaissance Technologies 1.7M +930.6K +120.3%
Maverick Capital 764.4K -918.49K -54.6%
MS Morgan Stanley 572.24K -882.17K -60.7%

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: ACTOVEGIN, Adaptate, AHA, AIPHAGAN, Alagille, Alembic, Alnylam, AML, analyzed, anemia, antiviral, Apr, ARALAST, aspire, atresia, AttenukineTM, Aug, AVISA, awaiting, barrier, Beam, biliary, bio, biodegradable, biographical, BlackRock, blended, Bocconi, booster, broke, Businesswomen, buyback, campaign, Cargo, CDE, CDTO, CEPROTIN, chairperson, Chancery, charitable, Charter, chemotherapy, cidofovir, Classical, CLP, CMML, CMV, CNDAP, coagulant, Coagulation, comfort, Croda, Cure, Dainippon, Darden, Dartmouth, decade, dexlansoprazole, diagnostic, Distinguished, DNA, Dolby, EE, EFPIA, Elizabeth, enantone, endorsed, endpoint, entail, evolution, Evozyne, Excellence, EXKIVITY, familial, family, feet, fell, Fellow, female, fibrostenotic, figure, firmwide, floor, foscarnet, FOSRENOL, Frazier, fSCIg, Gabriele, ganciclovir, gastroesophageal, genotypic, GERD, GHG, GPD, ground, Harvey, healing, heartburn, Hill, HilleVax, HSCT, hypersomnia, ID, ImmTOR, Immusoft, imperative, inbound, infertility, Inpatient, Intermuscular, intrahepatic, Intramuscular, invasion, ISP, IST, ITAC, iTTP, JCR, job, John, Jun, Kellogg, Kennedy, kg, Kimberly, Kobe, ku, Kymera, landfill, Lehman, leiomyomata, LIVETENCITY, LIVTENCITY, Lupin, LUPRON, Luxna, mantle, Maraganore, maralixibat, MCL, Mesothelin, MIB, Milan, Mirum, mobocertinib, modakafusp, movement, Mudd, myelomonocytic, needle, Northwestern, nuvaxovid, Oak, OBU, occupancy, OCE, OECD, Omicron, onset, operationalized, Oxford, pabinafusp, PANTHER, particulate, PAS, perioperative, pevonedistat, piggyBac, pillar, PIPL, platinum, Polytechnic, ponatinib, Poseida, pp, PreviPharma, progranulin, prompted, PROTHROMPLEX, PSU, puberty, rapid, rebound, redefine, Reed, Regensburg, Ricci, roll, Rome, RSU, Russian, Sandoz, Sanitary, satisfaction, scrutiny, SE, Selecta, shipping, Sigmapharm, signal, smart, societal, Sosei, spearheaded, spikevax, square, star, survival, symptomatic, synthesizing, TAC, tau, tenure, Tor, transferrin, Trieste, TV, unclarity, undelivered, undistributed, Unfit, unpunctured, unremitted, val, valganciclovir, variant, VBU, VECTIBIX, venetoclax, Vergata, Virginia, Waring, weighing, Wellesley, withdrawn, xeno, Yodogawa
Removed: abandon, acellular, activating, admitted, aerospace, Akzo, Alogliptin, Amato, amyotrophic, artery, Asahi, Assistant, Asthma, attenukine, Automobile, BacTrap, bid, Biodefense, bioterrorism, calcium, Centre, CEPI, Chase, checkpoint, claiming, Coalition, conformed, conjunction, COO, coronary, correlate, count, DAAO, de, deleveraging, depression, discontinuance, Dopamine, DOYUKAI, Dresser, eASC, EBARA, effort, Electron, EM, emphasizing, employer, Epidemic, ethical, existed, explore, feasibility, Fellowship, forma, Francisco, Fred, gained, GAVI, GM, grossed, Guangdong, harbor, headed, hearing, Hemoshear, hifibio, HPT, Huntington, Hutchinson, IAVI, IGF, incidental, INCJ, indemnification, indemnify, indenture, interacting, Interbrew, Inviragen, ITP, Jeffrey, JPMorgan, Kajima, Kawasaki, Keidanren, KEIZAI, Komatsu, labor, LATAM, leased, LigoCyte, longstanding, Louisiana, LPC, lymphocytic, Mallinckrodt, Marek, Markman, Masahiro, mature, Medipal, Melinda, Mersana, micro, Mississippi, Mizuho, Modell, moved, MUFG, Multilab, NEDD, negotiating, NEXON, NIDEC, Nihon, Nobel, Nomura, noncorporate, Novamed, Novimmune, officially, Opex, Organon, originating, outlined, Ovarian, oxidase, pace, pan, pattern, PENTASA, pill, pioglitazone, platelet, player, polio, positioning, PPTA, promising, Protease, provisional, PTH, pulmonary, purport, PvP, Rajeev, ran, reacquired, reacquisition, realignment, Redirected, remained, remove, Rent, repaid, resetting, retrospective, returning, Ricardo, seasoned, Shanghai, shared, side, Sony, SPRInT, sublease, Sunstar, Tabular, takeover, Techpool, tendered, trained, unfiled, user, velaglucerase, Venkayya, Virology, whilst, White, Yakuhin, Yasuhiko
Proxies
No filings